Fig. 1.

Strong, frequent, specific in vitro and ex vivo immune responses against mutant CALR epitopes in cells from healthy controls with a low CALR-mutant allelic burden. a IFN-γ ELISPOT results show responses against CALRLong1 peptide epitope in cells from two healthy individuals; (top left) in vitro results; (top right) representative in vitro wells; (bottom left) ex vivo results; (bottom right) representative ex vivo wells. b IFN-γ ELISPOT results show a response against CALRLong2 peptide epitope in cells from one individual with a low CALR-mutant allelic burden; (left) in vitro results; (right) representative in vitro wells. c (Top left) In vitro IFN-γ ELISPOT results show responses against CALRLong4 in cells from four healthy individuals; (top right) representative in vitro wells; (bottom left) Ex vivo IFN-γ ELISPOT responses against CALRLong4 peptide epitope in cells from three healthy individuals; (bottom right) representative ex vivo wells. d IFN-γ ELISPOT results show responses against CALRLong36 peptide epitope in cells from four healthy individuals; (top left) in vitro results, (top right) representative in vitro wells. (Bottom, left) Ex vivo results; (bottom, right) representative ex vivo wells. Error bars display standard error of the mean. *p ≤ 0.05 according to the distribution free resampling (DFR) rule. **p ≤ 0.05 according to the DFR2x rule [46]. GESUS1-GESUS4 are donor identifiers